- News
News
Welcome to the homepage of AIHTA!
AIHTA is an acadmic non-profit institute. At our website we wish to present our research and give support for health care decision-making. Here all of our reports are available for free. For further information please contact the AIHTA team.
In the News section you will find our most recent publications: newsletter, project-reports etc. Previous reports you might find via Research areas, Research projects and Repository.
Newsletter
Note: this content is only available in German.
Inhalt
- Editorial: „Des Kaisers neue Kleider“ - die Demenzforschung in der Krise
- Nutzenbewertung von KI-Gesundheitstechnologien
- Sektorübergreifende Versorgungsmodelle: Onkologische Brustkrebsversorgung in ausgewählten europäischen Ländern
- Strategien zur Reduzierung von Gewichtsdiskriminierung im Gesundheitswesen
- Screening auf psychische Erkrankungen bei Erwachsenen in der Primärversorgung
- Termine
- Themen-Vorschau
Announcement
Mental health screening of adults in primary care
With approximately one in five Austrian adults affected by mental illness annually, primarily depression (10%), anxiety disorders (7%), and substance use disorders (12%), screening in primary care settings could help identify and treat affected individuals early. Based on systematic reviews and evidence-based guidelines, this report analyses the evidence for mental health screening in primary care, identifies available screening tools, and discusses the requirements for implementing screening.
Publication: HTA Project Report No. 159: https://eprints.aihta.at/1544
Contact: Julia Kern
Newsletter
Note: this content is only available in German.
Inhalt
- Editorial: Paxlovid: ein „Magic Bullet” zwischen Mythos und Evidenz
- Ersatzprodukte für Fleisch und Milch: Effekte auf Gesundheit (und Umwelt)
- Nationale Strategien für seltene Erkrankungen
- Früherkennung von Darmkrebs bei Personen mit familiärem Risiko
- Next-Generation-Sequencing (NGS)-Panels für Intelligenzminderung oder globale Entwicklungsverzögerung
- Termine
- Themen-Vorschau
Announcement
Horizon Scanning in Oncology - Fact Sheets
We are pleased to introduce you seven new Fact Sheets.
Fact Sheet Nr. 184 (July 2024)
Toripalimab (Loqtorzi®) in combination with cisplatin and gemcitabine for the first-line treatment of recurrent, not amenable to surgery or radiotherapy, or metastatic nasopharyngeal carcinoma (NPC)
Fact Sheet Nr. 185 (July 2024)
Toripalimab (Loqtorzi®) with cisplatin and paclitaxel for the first-line treatment of unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma (OSCC)
Fact Sheet Nr. 186 (July 2024)
Zolbetuximab (Vyloy®) with chemotherapy for the first-line treatment of locally advanced unresectable or metastatic HER2?negative gastric or gastro-oesophageal junction (GEJ) adenocarcinoma
Fact Sheet Nr. 187 (July 2024)
Encorafenib (Braftovi®) in combination with binimetinib (Mektovi®) for the treatment of advanced non-small cell lung cancer (NSCLC)
Fact Sheet Nr. 188 (July 2024)
Pembrolizumab (Keytruda®) with enfortumab vedotin (Padcev®) for the first-line treatment of unresectable or metastatic urothelial carcinoma
Fact Sheet Nr. 189 (July 2024)
Amivantamab (Rybrevant®) in combination with carboplatin and pemetrexed for the treatment of advanced non-small cell lung cancer (NSCLC)
Fact Sheet Nr. 190 (July 2024)
Atezolizumab (Tecentriq®) as monotherapy for the first-line treatment of advanced NSCLC
Newsletter
Note: this content is only available in German.
Inhalt
- Editorial: Korruptionsforschung als aktiver Beitrag zum Handeln gegen Korruption
- Stereotaktische Strahlentherapie, Protonentherapie und irreversible Elektroporation zur Behandlung von lokalisiertem Prostatakrebs
- Analyse österreichischer Krankenversicherungsdaten zur Inanspruchnahme psychischer Gesundheitsleistungen von Frauen vor und während der Peripartalperiode
- D-Dimer- und Troponin-Point of Care Tests (POCT)
- Technologien zur Hochdurchsatz-Analyse genetisch-genomischer Datensätze mittels massiv-paralleler Sequenzierung
- Termine
- Themen-Vorschau
Announcement
Uptake of Mental Health Benefits in Women Before and During the Perinatal Period: An Analysis of Austrian Health Insurance Data
On average, one in five women suffer from a mental illness during the perinatal period (pregnancy up to 1 year after birth. So far, it has been unknown how many women claim mental health services during this period. The analysis of pseudonymised insurance data revealed that around 20% of women in Austria who gave birth in 2017 and 2018 used at least one of five examined mental health services during the perinatal period. However, very few specialised perinatal mental health services are available in Austria, with regional disparities. The quality of existing services should be evaluated, and gaps in care need to be closed.
Publication: HTA Project Report No. 154: https://eprints.aihta.at/1535/
Contact: Ingrid Zechmeister-Koss
Announcement
Horizon Scanning in Oncology - Fact Sheets
We are pleased to introduce you four new Fact Sheets.
Fact Sheet No. 180 (June 2024)
Erdafitinib (Balversa®) as monotherapy for the treatment of unresectable or metastatic urothelial carcinoma (UC)
Fact Sheet No. 181 (June 2024)
Odronextamab (Ordspono®) as monotherapy for the treatment of relapsed or refractory follicular lymphoma (r/r FL) or diffuse large B?cell lymphoma (r/r DLBCL)
Fact Sheet No. 183 (June 2024)
Epcoritamab (Tepkinly®) as monotherapy for the treatment of relapsed or refractory follicular lymphoma (FL)
Announcement
Stereotactic radiotherapy, proton therapy and irreversible electroporation for the treatment of localised prostate cancer
This update report assesses three alternative treatments to radical therapies for localised prostate cancer (PCA): irreversible electroporation (IRE) uses electrode needles to target and destroy carcinoma tissue; stereotactic radiation therapy (SBRT) and proton therapy (PT) are forms of external beam radiation therapy, SBRT delivers high dose radiation in fewer fractions than conventional or moderate fractionation radiation, while PT delivers high-dose ionizing radiation with great precision.
The current evidence remains insufficient to conclude that IRE, SBRT, and PT improve outcomes in terms of survival and quality of life, as well as the avoidance of radical invasive procedures like prostatectomy, compared to conventional therapies. Recent RCTs on SBRT show minor differences in survival rates compared to conventional fractionation radiation in low- and intermediate-risk PCa. Further research is necessary for definitive conclusions.
Publication: Project Report No.: 107/1. Update: https://eprints.aihta.at/1530/
Contact: Judit Erdös
Newsletter
Note: this content is only available in German.
Inhalt
- Editorial: HTA-Patient*innenschulungen in EUCAPA
- Thermoablation von benignen Schilddrüsenknoten
- Perkutane transluminale Koronarangioplastie mit medikamentenbeschichtetem Ballon bei koronarer Herzkrankheit
- Elektrokonvulsionstherapie bei therapieresistenter Depression und therapieresistenter Schizophrenie
- Renale Denervierung bei therapieresistenter Hypertonie
- Perkutaner transfemoraler heterotoper Trikuspidalklappenersatz bei Trikuspidalinsuffizienz
- Termine
- Themen-Vorschau
Announcement
Evaluation of individual medical procedures - Reports 2024
We are pleased to introduce our new reports.
Decision Support Documents 2024:
- DSD 139: Caval valve implantation for severe tricuspid regurgitation https://eprints.aihta.at/1525
- DSD 140: Electroconvulsive therapy in treatment-resistant depression and treatment-resistant schizophrenia https://eprints.aihta.at/1526
- DSD 141: Thermoablation for benign thyroid nodules https://eprints.aihta.at/1527
+ 2 Updates
- DSD 24: Percutaneous transluminal coronary angioplasty (PTCA) with drug-eluting balloon (DEB) in patients with coronary artery disease (CAD). 3. Update 2024 https://eprints.aihta.at/1528
- DSD 45: Renal denervation (RDN) in patients with treatment resistant hypertension. 2. Update 2024 https://eprints.aihta.at/1529
